Evidence map›Paper›PMID 25973434›Full record

Trial reportJournal of immunology research2015

The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China.

Qiu Qian, Liang Liuqin, Li Hao, Yuan Shiwen, Zhan Zhongping, Chen Dongying, Lian Fan, Xu Hanshi, Yang Xiuyan, Ye Yujin

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Bromocriptine in Rheumatic Diseases: A Review.European journal of rheumatology · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Prolactin and Autoimmunity.Frontiers in immunology · 2018
    Review
  7. Article
  8. What Causes Lupus Flares?Current rheumatology reports · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Qiu QianDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Liang LiuqinDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Li HaoDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Yuan ShiwenDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Zhan ZhongpingDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Chen DongyingDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Lian FanDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Xu HanshiDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Yang XiuyanDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Ye YujinDepartment of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProlactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the postpartum disease relapse.

methodsPatients were randomly divided into the treatment group (bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery) and the control group. All the patients were followed up for 12 months. Clinical features were recorded every 4 weeks. Serum prolactin and estradiol levels were measured at the second week and the second month after delivery. The endpoint of the study was disease relapse and defined when SLEDAI score increased by ≥3 points from the antenatal baseline.

results(1) Serum levels of prolactin and estradiol decreased significantly in bromocriptine treatment group at the second week (P < 0.001) and second month (P < 0.05) after delivery compared to control group. (2) The relapse rate of the treatment group was lower than the control group (χ (2) = 4.68, P = 0.0305).

conclusionsTwo weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.

Indexed as

Symptom Flare UpAdultBromocriptineChinaDopamine AgonistsEstradiolFemaleHumansHyperprolactinemiaLupus Erythematosus, SystemicPostpartum PeriodPregnancyProlactinRandom AllocationSecondary PreventionSeverity of Illness IndexBromocriptineDopamine AgonistsEstradiolProlactin

Identifiers

PMID25973434
PMCPMC4418009
OpenAlexW2056206983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.